Scholars Central

Review articlePublished 21 Jul 2016

Continuing evolution of the role of Ã?²-blockers in the treatment of hypertension

Authors: Thomas D Giles

Clinical Practice

Volume 5 · Issue 6 · Pages 773

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The β-blockers have evolved into one of the most prescribed classes of drugs for the treatment of cardiovascular disease in general, and hypertension in particular. However, the class is one of the more heterogenous groups in pharmacological agents. The evolution of the β-blockers has included increased selectivity for the β1 receptor (cardioselective) and, more recently, development of β-blockers with vasodilating properties. As a result of this evolution, the current vasodilating β-blockers, i.e., nebivolol and carvedilol, have a better hemodynamic profi le and are devoid of many of the troublesome side effects, for example, fatigue, sexual dysfunction and increased insulin resistance and disturbances in glucose metabolism, found in the traditional β-blockers. Nebivolol produces vasodilation by a mechanism that includes increased bioavailability of nitric oxide that may bring other benefi ts. With these improvements in design, the future for the use of β-blockers appears bright.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Clinical Practice.

All its articles

Article · 28 Mar 2025

Using

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Practice
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Thomas D Giles”